Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California.
IPO Year: 2018
Exchange: NASDAQ
Website: axonics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2024 | Outperform → Peer Perform | Wolfe Research | |
| 7/19/2023 | $69.00 | Outperform | Robert W. Baird |
| 7/13/2023 | $70.00 | Overweight | KeyBanc Capital Markets |
| 5/23/2023 | $75.00 | Buy | CL King |
| 4/14/2023 | $75.00 | Buy | Mizuho |
| 3/24/2023 | $71.00 | Hold → Buy | Needham |
| 10/21/2022 | $85.00 | Outperform | RBC Capital Mkts |
| 10/12/2022 | $75.00 | Hold | Jefferies |
| 10/10/2022 | Buy → Hold | Needham | |
| 4/6/2022 | $69.00 | Outperform | Wolfe Research |
Wolfe Research downgraded Axonics Modulation from Outperform to Peer Perform
Robert W. Baird initiated coverage of Axonics Modulation with a rating of Outperform and set a new price target of $69.00
KeyBanc Capital Markets initiated coverage of Axonics Modulation with a rating of Overweight and set a new price target of $70.00
CL King initiated coverage of Axonics Modulation with a rating of Buy and set a new price target of $75.00
Mizuho initiated coverage of Axonics Modulation with a rating of Buy and set a new price target of $75.00
Needham upgraded Axonics Modulation from Hold to Buy and set a new price target of $71.00
RBC Capital Mkts initiated coverage of Axonics Modulation with a rating of Outperform and set a new price target of $85.00
Jefferies initiated coverage of Axonics Modulation with a rating of Hold and set a new price target of $75.00
Needham downgraded Axonics Modulation from Buy to Hold
Wolfe Research initiated coverage of Axonics Modulation with a rating of Outperform and set a new price target of $69.00